We report a case of baclofen withdrawal syndrome resulting from oral baclofen underdosing. A 24-year-old woman with type 1 neurofibromatosis receiving long-term baclofen therapy was admitted with presumed pneumonia which was successfully treated with antibiotics. The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen. Baclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit.
Fever affects up to 70% of patients in the intensive care unit (ICU), and its clinical impact cannot be emphasized enough 1 . Medication withdrawal is frequently overlooked as a potential cause of fever. We describe a patient with prolonged fever and autonomic instability who was receiving long-term baclofen therapy. Continuous fever persisted for five weeks despite early reinstitution of oral baclofen at a lower than preadmission dosage. The patient defervesced within 24 hours of resuming her preadmission daily regimen of oral baclofen.
CASE HISTORY
A 24-year-old woman with type 1 neurofibromatosis was taken to the emergency room by her mother with complaints of one week of nausea, weakness and decreased appetite, and one day of shortness of breath. The patient's mother denied the presence of cough or fever. At baseline, the patient was quadriparetic and wheelchair-bound but was alert and communicative. She was cared for by her family at home, and had not been hospitalized for seven years. Her home medications were baclofen 10 mg orally three times daily and lorazepam 1 mg orally twice daily as reported by the patient's mother. On examination in the emergency room, the temperature was 36.5°C, pulse 100 beats per minute, blood pressure 150/100 mmHg, and respiratory rate 14 breaths per minute, with oxygen haemoglobin saturation of 90 per cent while breathing supplemental oxygen of FiO 2 1.0 via a full face mask.
On auscultation of the chest, crackles were heard at the base of the right lung. The rest of the physical examination including the ears, nose, and throat, cardiovascular, abdominal, skin, and extremities examination revealed no abnormalities. Neurological examination demonstrated intact mental status, quadriparesis and significant spasticity of all four extremities. According to the patient's mother, this was not different from her baseline.
She developed progressive respiratory distress during her six-hour stay in the emergency room. She was orally intubated and placed on mechanical ventilation. Her arterial blood gas values were pH of 7.49, partial pressure of carbon dioxide (P a CO 2 ) of 50 mmHg, and partial pressure of oxygen (P a O 2 ) of 54 mmHg while receiving assist control volume cycled mechanical ventilation with FiO 2 of 1.0, and positive end-expiratory pressure of 5 cmH 2 O. A chest radiograph showed opacity in the right middle lobe and right lower lobe suggestive of atelectasis or infiltrate. The initial laboratory values were notable for sodium of 117 mmol/l, white blood cell count of 14,500×10 9 /l, D-dimer of 2.76 µg/ml (normal 0.22-0.74 µg/ml), and serum osmolarity of 252 mOsm/kg. Her blood, urine, and tracheal aspirate samples were sent for culture, and intravenous heparin and broadspectrum antibiotics (piperacillin/tazobactam and azithromycin) were administered. She received midazolam and fentanyl by infusion.
Computed tomographic (CT) angiography of the chest and lower extremities showed consolidation of the right middle lobe and right lower lobe, without evidence of pulmonary embolus or deep venous thrombosis. Doppler ultrasound of the bilateral lower extremities was similarly negative for deep vein thrombosis. Anticoagulation was discontinued, and the patient was admitted to the medical ICU with the diagnosis of acute on chronic respiratory failure due to possible community-acquired or aspiration pneumonia. Serum sodium and osmolarity normalized after fluid resuscitation with normal saline, oxygenation improved, and white blood cell count decreased to 6,500×10 9 /l over the next 72 hours.
Twelve hours after the admission to the ICU (approximately 18 hours after her arrival to the emergency room), she developed a fever of 38.9°C. Fibreoptic bronchoscopy with bronchoalveolar lavage was performed on the first day of hospitalization (following administration of the first dose of antibiotics) to evaluate for possible aspiration, and demonstrated patent airways, normal appearing mucosa, and minimal serous bronchial secretions. Her bronchoalveolar lavage, blood and urine cultures remained negative. She remained continuously febrile after five days of piperacillin/tazobactam and azithromycin. Possible baclofen or benzodiazepine withdrawal was suspected, and baclofen 10 mg orally three times daily and lorazepam 1 mg orally twice daily were resumed. The patient remained febrile despite reinstituting these medications. Lumbar puncture was deferred because of a low clinical suspicion for meningitis, multiple previous spinal fusion surgeries, and extensive spinal neurofibromatosis. Her mental status remained intact, and limb spasticity remained unchanged. The antibiotic regimen was changed to include coverage for possible nosocomial pathogens.
A repeat bronchoscopy was performed on hospital day 10 to evaluate for possible ventilator-associated pneumonia; however, the findings were unremarkable. All cultures, including bronchoalveolar lavage, tracheal aspirate, blood and urine remained negative. All medications with the exception of lorazepam and baclofen were discontinued for suspected druginduced fever. However, the patient remained febrile. The patient was refusing tracheostomy after failing an early extubation attempt. She was extubated on hospital day 25. Lorazepam and baclofen were witheld to minimize sedation. She was alert and communicative, and was not receiving any medications. The patient developed progressive hypercapnic and hypoxaemic respiratory failure, and was orally re-intubated after one week. She then had a higher continuous fever to 40.5°C, and demonstrated signs of autonomic instability with systolic blood pressure ranging from 60 to 220 mmHg, and pulse ranging from 50 to 150 beats per minute two days after lorazepam and baclofen were withheld. Baclofen 10 mg orally three times daily, lorazepam 1 mg intravenously twice daily, and broad spectrum antibiotics were reinstituted without effect.
A broad differential diagnosis including possible infectious, malignant, inflammatory, thromboembolic, and neurologic causes of the prolonged continuous fever was systematically investigated during her ICU stay (Table 1 ). This extensive investigation of the cause of her fever was unrevealing. On hospital day 39, upon repeat discussion with the patient's mother, it was established that the patient had been taking a dose of baclofen of 30 mg orally four times daily. Her baclofen dose was titrated up quickly over the next 48 hours, and antibiotics were discontinued. Her autonomic instability and fever entirely resolved within 24 hours of achieving full home dosing ( Figure  1 
DISCUSSION
We report a case of baclofen withdrawal syndrome resulting from oral baclofen underdosing. Our patient had persistent fever while receiving 25 per cent of her prior dose of oral baclofen with a higher fever and autonomic instability developing after baclofen was withheld. Clinical diagnosis of baclofen withdrawal syndrome was established after careful evaluation of other potential aetiology of prolonged fever in the ICU, including infectious, malignant, inflammatory, thromboembolic, neurologic, and medication-related causes. It is unlikely that her symptoms were due to benzodiazepine withdrawal since she was receiving midazolam infusion during the first four days of her hospitalization, and the preadmission dose of oral lorazepam after the fifth day of her hospitalization. It is also unlikely that prolonged fever was due to presumed pneumonia since her oxygenation improved and white blood cell count decreased after receiving antibiotics for three days. The patient's autonomic instability and fever entirely resolved within 24 hours of achieving full prior dosage of oral baclofen.
Baclofen is the analogue of the inhibitory neurotransmitter gamma aminobutyric acid (GABA). It relieves spasticity and rigidity in patients with cerebral and spinal cord injuries by activating presynaptic GABA B receptors of type Ia muscle spindle afferents 2, 3 . Concomitant inhibition of excitatory neuro-transmitter release (possibly substance P) from nociceptive skin afferents may augment the muscle relaxant effect of baclofen 4 . GABA B receptors in the spinal cord are down-regulated after a week of baclofen therapy in an animal model 5 . Thus, abrupt withdrawal of baclofen may be associated with rebound excitation at all levels of the neuro-axis that may not be overcome by the administration of lower dosages of baclofen or other GABA agonists [6] [7] [8] [9] .
Baclofen withdrawal following abrupt discontinuation of intrathecal or oral baclofen therapy is a lifethreatening and even fatal syndrome [6] [7] [8] [9] [10] . Symptoms including fever, autonomic dysregulation, sepsis-like syndrome, muscle spasticity, dyskinesia, psychosis and seizure have been reported 6, 7, 11, 12 . Baclofen underdosing during attempts to taper oral baclofen or replace intrathecal with oral baclofen may cause severe baclofen withdrawal syndrome 8, 9 . Withdrawal symptoms begin 12 hours to several days after baclofen dosage is reduced or discontinued, and resolve approximately 24 to 72 hours after baclofen administration is resumed 8 . Patients receiving oral baclofen doses of more than 80 mg daily are more likely to experience withdrawal syndrome, although abrupt discontinuation of dosages as low as 30 mg daily may lead to withdrawal symptoms 13 . Withdrawal from intrathecal baclofen appears to cause more severe symptoms than withdrawal from oral baclofen [8] [9] [10] . This may in part result from inadvertent underdosing of oral baclofen when used for substituting intrathecal baclofen 8 . Baclofen does not readily cross the bloodbrain barrier, so high oral doses are required before clinical benefits occur 14 
